Drug Profile
Influenza A virus H1N1 vaccine - iBio/Fraunhofer USA Center for Molecular Biotechnology
Alternative Names: H1N1 vaccine - iBio; H1N1 virus vaccine - iBio; HAC1 vaccine; Influenza A virus H1N1 vaccine - iBio; Swine flu vaccine - iBioLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator iBio Inc
- Developer Fraunhofer USA Center for Molecular Biotechnology; iBio Inc
- Class Influenza A virus H1N1 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus H1N1 subtype
Most Recent Events
- 03 May 2016 No recent reports on development identified - Phase-I for Influenza-A virus H1N1 subtype (Prevention) in USA (IM)
- 21 Mar 2012 Final immunogenicity and adverse event data from a phase I trial in Influenza-A virus H1N1 subtype released by Fraunhofer USA Center for Molecular Biotechnology/iBio ,
- 03 Jun 2011 Interim immunogenicity and safety data from a preclinical trial in Influenza-A virus H1N1 subtype released by Fraunhofer CMB